Policy | September 14, 2023
Cabinet approves foreign investment of up to Rs. 9,589 crore in Suven Pharmaceuticals
The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited
The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Casper Pharma is a Hyderabad based SEZ company engaged in the formulations business. Post-purchase of shares, the target entity would become a wholly-owned subsidiary of SPL
Suven Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Subscribe To Our Newsletter & Stay Updated
